NORCROSS, Ga., March 17, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, today announced it has appointed Henry Brem, M.D., as an independent director to its Board of Directors. Dr. Brem is an internationally recognized neurosurgeon-scientist and leader in translational medicine. He serves as the Henry Brem Professor of Neurosurgery at Johns Hopkins University and previously ...

PresentationI'd now like to turn the call over to your moderator, Michael Cozart of LifeSci Consulting. Please go ahead, Michael.Good afternoon, and welcome to the Galectin Therapeutics Virtual KOL event. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the Galectin website following the conclusion of the event.Michael Cozart Thanks, Tara, and good afternoon, everyone, and thank you for joining today's KOL webinar. My name is Michael Cozart, and I'm ...

Summary of Galectin Therapeutics KOL Event on Belapectin for MASH Cirrhosis Company and Industry Overview - **Company**: Galectin Therapeutics (NasdaqCM: GALT) - **Industry**: Treatment of MASH (Metabolic Associated Steatotic Hepatitis) cirrhosis with portal hypertension Core Points and Arguments - **Rising Prevalence of MASH Cirrhosis**: The prevalence of MASH cirrhosis is increasing in the U.S., primarily due to rising obesity and type 2 diabetes rates. Over 5 million individuals are estimated to be living with MASH cirrhosis, while fewer than 12,000 liver transplants were performed last year, highlighting a significant unmet medical need [4][5] - **Belapectin's Mechanism**: Belapectin is a complex carbohydrate that targets Galectin-3, a protein linked to fibrosis. It has shown potential in reducing fibrosis and inflammation in preclinical studies, making it a novel treatment option for MASH cirrhosis and portal hypertension [5] - **Market Opportunity**: The economic burden of MASH cirrhosis, combined with the lack of FDA-approved pharmacological therapies, presents a multi-billion dollar market opportunity for belapectin [6] - **Clinical Trial Results**: The NAVIGATE trial, a pivotal study, demonstrated that belapectin significantly reduced the development of new esophageal varices in patients with MASH cirrhosis and portal hypertension. The 2 mg/kg dose showed a 50% reduction in new varices compared to placebo [16][31] - **Safety Profile**: The safety profile of belapectin was reported as excellent, with no significant adverse events or drug-induced liver injury observed [17][31] Additional Important Content - **Current Treatment Landscape**: There are currently no approved treatments for NASH cirrhosis. Management primarily involves lifestyle interventions and monitoring for complications [10] - **Biomarker Insights**: The trial included various biomarkers to assess liver stiffness and fibrosis, showing that belapectin treatment led to a reduction in liver stiffness and other fibrosis markers compared to placebo [22][30] - **Regulatory Discussions**: Galectin Therapeutics is focused on advancing discussions with regulatory agencies and identifying partners to further develop the belapectin program [33] - **Non-Invasive Diagnosis**: There is a shift away from liver biopsies for diagnosing cirrhosis, with reliance on non-invasive modalities like VCTE and ELF scores [38][40] This summary encapsulates the key points discussed during the Galectin Therapeutics KOL event, emphasizing the potential of belapectin in addressing the unmet needs of patients with MASH cirrhosis and portal hypertension.

NORCROSS, Ga., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, March 10, 2026 at 12:00 PM ET. To register, click here. The event will focus on the unmet need and current treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertensi ...

Core Viewpoint - Galectin Therapeutics Inc. is under investigation for potential violations of federal securities laws following a significant drop in its stock price after an FDA communication regarding its drug development program [1][3]. Group 1: Company Developments - On December 19, 2025, Galectin Therapeutics announced that the FDA provided a written response to its Type C meeting request concerning the development of belapectin, an investigational galectin-3 inhibitor [2]. - The FDA's response converted the company's request for an in-person or teleconference meeting into a written format, indicating that while there is alignment on the proposed patient population for a registration trial, key aspects of the trial design remain unresolved [2]. Group 2: Market Reaction - Following the FDA's communication, Galectin's stock price experienced a decline of over 28% on the same day [3].

Core Viewpoint - Levi & Korsinsky has initiated an investigation into Galectin Therapeutics Inc. for potential violations of federal securities laws following a significant drop in the company's stock price after FDA communications regarding its drug development program [1][3]. Group 1: Company Developments - Galectin Therapeutics announced on December 19, 2025, that the FDA provided a written response to its Type C meeting request concerning the development of belapectin, an investigational galectin-3 inhibitor [2]. - The FDA's response converted the company's request for an in-person or teleconference meeting into a written format, indicating that while there is alignment on the proposed patient population for a registration trial, key aspects of the trial design remain unresolved [2]. Group 2: Market Reaction - Following the FDA's communication, Galectin's stock price experienced a decline of over 28% on December 19, 2025, reflecting investor concerns regarding the unresolved aspects of the clinical trial design [3]. Group 3: Legal Context - Levi & Korsinsky, a recognized securities litigation firm, has a history of securing significant recoveries for shareholders and has been ranked among the top securities litigation firms in the U.S. for seven consecutive years [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Galectin Therapeutics Inc. and its officers or directors [1] Group 1: Company Developments - On December 19, 2025, Galectin announced that the FDA provided a written response to its Type C meeting request regarding the development program for belapectin, an investigational galectin-3 inhibitor [3] - The FDA's response converted the initial request for an in-person or teleconference meeting to a written format, indicating that key aspects of the trial design remain unresolved despite alignment on the proposed patient population for a registration trial [3] Group 2: Market Reaction - Following the news of the FDA's response, Galectin's stock price fell by $1.78 per share, or 28.9%, closing at $4.38 per share on December 19, 2025 [4]

Core Viewpoint - The Schall Law Firm is investigating Galectin Therapeutics Inc. for potential violations of securities laws related to misleading statements and failure to disclose important information to investors [1][2]. Group 1: Investigation Details - The investigation centers on whether Galectin issued false or misleading statements regarding its development program for belapectin, an investigational galectin-3 inhibitor [2]. - On December 19, 2025, Galectin announced that the FDA provided a written response to its Type C meeting request, which was initially sought as an in-person or teleconference meeting [2]. - Following the announcement, Galectin's shares experienced a significant decline of 28.9% on the same day [2]. Group 2: Legal Representation - The Schall Law Firm is representing investors globally and specializes in securities class action lawsuits and shareholder rights litigation [3]. - Shareholders who suffered losses are encouraged to contact the firm for a free discussion of their rights [3].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Galectin Therapeutics Inc. and its officers and directors [1] Group 1: Company Developments - On December 19, 2025, Galectin announced that the FDA provided a written response to its Type C meeting request regarding the development program for belapectin, an investigational galectin-3 inhibitor [3] - The FDA's response converted the initial request for an in-person or teleconference meeting to a written format, indicating that key aspects of the trial design remain unresolved despite alignment on the proposed patient population for a registration trial [3] Group 2: Market Reaction - Following the news of the FDA's response, Galectin's stock price fell by $1.78 per share, or 28.9%, closing at $4.38 per share on December 19, 2025 [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Galectin Therapeutics Inc. and its officers or directors [1] Group 1: Company Developments - Galectin Therapeutics announced that the FDA provided a written response to its Type C meeting request regarding the development program for belapectin, an investigational galectin-3 inhibitor [2] - The FDA's response converted the initial request for an in-person or teleconference meeting to a written format, indicating ongoing communication between the company and the agency [2] - Galectin plans to pursue a follow-up Type C meeting with the FDA to finalize the remaining components of its next clinical trial design, although key aspects of the trial design remain unresolved [2] Group 2: Market Reaction - Following the announcement regarding the FDA's response, Galectin's stock price fell by $1.78 per share, representing a 28.9% decrease, closing at $4.38 per share on December 19, 2025 [3]